Panobinostat to revert bortezomib resistance

1Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

In this issue of Blood, Richardson et al present convincing results demonstrating that panobinostat, an oral pan-deacetylase inhibitor, in combination with bortezomib and dexamethasone, can recapture responses in bortezomib-refractory multiple myeloma (MM).1 © 2013 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Moreau, P. (2013, October 3). Panobinostat to revert bortezomib resistance. Blood. https://doi.org/10.1182/blood-2013-08-522417

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free